Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

The GLP-1 drugs continue to make headlines due to their FDA-approved uses for treating Type 2 diabetes and obesity, but a ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Weight loss tops many folks’ list of New Years resolutions, and lots of people are turning to cutting-edge weight-los ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

GLP-1, or Glucagon-like peptide-1, medications, similar to Ozemppic and Wegovy, are becoming more accessible, and while the ...

Ozempic has fast become a household name. In addition to helping people with diabetes manage their blood sugar levels, this ...

Insurers said one major driver of higher premiums is the growing popularity of a relatively new class of injectable drugs to ...

The diabetes drugs glucagon-like peptide 1, or GLP-1, are effective in dramatic and rapid weight loss, but one of the ...